TriangleDISEASE & TREATMENT SETTING
FOTIVDA: refractory Renal cell carcinoma after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Broader topic: Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- refractory
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following two or more prior systemic therapies
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for FOTIVDA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Study evidence for this setting
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Molecular-Guided Therapy for Childhood Cancer
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice